EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Sodium‐glucose co‐transporter 2 inhibitors reduce the intravitreal anti‐ VEGF treatment necessity in eyes with early diabetic macular oedema: A post‐hoc analysis focusing on the fellow eye of the COMET trial

Tomoaki Tatsumi iD, Yoko Takatsuna iD, Ryoichi Ishibashi iD, Masaya Koshizaka iD, Tomomi Kaiho, Toshiyuki Oshitari iD, Yuki Shiko, Noriko Asaumi, Shuichi Yamamoto, Koutaro Yokote iD, Takayuki Baba iD

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16636 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Tomoaki Tatsumi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, Chuo-ku, Chiba, Japan. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Diabetes Mellitus, Type 2, Diabetic Retinopathy, Macular Edema. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Taisho Toyama Pharmaceutical Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

This study aimed to determine the efficacy of oral administration of sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) therapy for early diabetic macular oedema (DMO). Materials and Methods We conducted a post‐hoc analysis of the COMET trial, a prospective, randomized, parallel, investigator‐driven protocol. Sixty patients with DMO eligible for anti‐vascular endothelial growth factor (VEGF) therapy were randomized to receive either the SGLT2i luseogliflozin or sulfonylurea (SU) glimepiride. Intravitreal ranibizumab (IVR) injections were administered per protocol to both eyes over 48 weeks. For this analysis, we included eyes with no or mild macular oedema at baseline and excluded those that had received treatment within a defined period prior to enrolment. Best‐corrected visual acuity (BCVA), central retinal thickness (CRT), and the number of IVR injections were compared between the SGLT2i and SU groups.

Results

At baseline, 20 eyes in the SU group and 22 eyes in the SGLT2i group did not require IVR. Changes in BCVA and CRT did not differ significantly between the groups. IVR was required in 9 of 20 eyes in the SU group versus 2 of 22 eyes in the SGLT2i group. The rate of the first IVR was significantly lower in the SGLT2i group.

Conclusions

Systemic SGLT2i therapy reduced the need for intravitreal anti‐VEGF treatment in eyes with early and mild DMO. These results suggest that SGLT2i may be effective in preventing the progression of early and mild DMO.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiogenesis InhibitorsDiabetes Mellitus, Type 2Diabetic RetinopathyMacular EdemaRanibizumabSodium-Glucose Transporter 2 InhibitorsVascular Endothelial Growth Factor AAgedFemaleHumansMaleMiddle AgedIntravitreal InjectionsProspective StudiesSulfonylurea CompoundsTomography, Optical CoherenceTreatment OutcomeVisual AcuitySorbitol

Stichwörter der Autor:innen

SGLT2 inhibitoranti‐VEGF treatmentclinical trialdiabetic macular oedemadiabetic retinopathysulphonylureas

Substanzen

1,5-anhydro-1-(5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl)-1-thioglucitolAngiogenesis InhibitorsglimepirideRanibizumabSodium-Glucose Transporter 2 InhibitorsSulfonylurea CompoundsVascular Endothelial Growth Factor AVEGFA protein, humanSorbitol

Autor:innen und Institutionen

  • Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, Chuo-ku, Chiba, Japan.
  • Department of Ophthalmology, Chiba Rosai Hospital, Ichihara, Chiba, Japan.
  • Department of Endocrinology, Haematology, and Gerontology, Chiba University Graduate School of Medicine, Chuo-ku, Chiba, Japan.
  • Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Kimitsu Chuo Hospital, Kisarazu, Chiba, Japan.
  • Department of Nutrition and Metabolic Medicine, Center for Preventive Medical Science, Chiba University, Inage-ku, Chiba, Japan.
  • Department of Ophthalmology, International University of Health and Welfare School of Medicine, Narita, Chiba, Japan.

ORCID-Profile: Tomoaki Tatsumi, Yoko Takatsuna, Ryoichi Ishibashi, Masaya Koshizaka, Toshiyuki Oshitari, Koutaro Yokote, Takayuki Baba

Förderung

  • Taisho Toyama Pharmaceutical Company

Zitieren

APA

Tatsumi, T., Takatsuna, Y., Ishibashi, R., Koshizaka, M., Kaiho, T., Oshitari, T., Shiko, Y., Asaumi, N., Yamamoto, S., Yokote, K., & Baba, T. (2025). Sodium‐glucose co‐transporter 2 inhibitors reduce the intravitreal anti‐ VEGF treatment necessity in eyes with early diabetic macular oedema: A post‐hoc analysis focusing on the fellow eye of the COMET trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16636

Vancouver

Tatsumi T, Takatsuna Y, Ishibashi R, Koshizaka M, Kaiho T, Oshitari T, et al. Sodium‐glucose co‐transporter 2 inhibitors reduce the intravitreal anti‐ VEGF treatment necessity in eyes with early diabetic macular oedema: A post‐hoc analysis focusing on the fellow eye of the COMET trial. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16636

BibTeX
@article{Tatsumi2025,
  author = {Tatsumi, Tomoaki and Takatsuna, Yoko and Ishibashi, Ryoichi and Koshizaka, Masaya and Kaiho, Tomomi and Oshitari, Toshiyuki and Shiko, Yuki and Asaumi, Noriko and Yamamoto, Shuichi and Yokote, Koutaro and Baba, Takayuki},
  title = {Sodium‐glucose co‐transporter 2 inhibitors reduce the intravitreal anti‐ VEGF treatment necessity in eyes with early diabetic macular oedema: A post‐hoc analysis focusing on the fellow eye of the COMET trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16636}
}
Kostenlos starten →